Titre : Dasatinib

Dasatinib : Questions médicales fréquentes

Termes MeSH sélectionnés :

Memory B Cells
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Dasatinib : Questions médicales les plus fréquentes", "headline": "Dasatinib : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Dasatinib : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-06", "dateModified": "2025-05-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Dasatinib" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pyrimidines", "url": "https://questionsmedicales.fr/mesh/D011743", "about": { "@type": "MedicalCondition", "name": "Pyrimidines", "code": { "@type": "MedicalCode", "code": "D011743", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.742" } } }, "about": { "@type": "MedicalCondition", "name": "Dasatinib", "alternateName": "Dasatinib", "code": { "@type": "MedicalCode", "code": "D000069439", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mohammad Raish", "url": "https://questionsmedicales.fr/author/Mohammad%20Raish", "affiliation": { "@type": "Organization", "name": "Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia." } }, { "@type": "Person", "name": "Kirk N Campbell", "url": "https://questionsmedicales.fr/author/Kirk%20N%20Campbell", "affiliation": { "@type": "Organization", "name": "Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York." } }, { "@type": "Person", "name": "Edgar A Jaimes", "url": "https://questionsmedicales.fr/author/Edgar%20A%20Jaimes", "affiliation": { "@type": "Organization", "name": "Renal Service, Memorial Sloan Kettering Cancer Center, New York, New York." } }, { "@type": "Person", "name": "Evren U Azeloglu", "url": "https://questionsmedicales.fr/author/Evren%20U%20Azeloglu", "affiliation": { "@type": "Organization", "name": "Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York." } }, { "@type": "Person", "name": "Ajaz Ahmad", "url": "https://questionsmedicales.fr/author/Ajaz%20Ahmad", "affiliation": { "@type": "Organization", "name": "Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk.", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36351924", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-022-34408-0" } }, { "@type": "ScholarlyArticle", "name": "JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission.", "datePublished": "2024-07-17", "url": "https://questionsmedicales.fr/article/39020445", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13075-024-03374-x" } }, { "@type": "ScholarlyArticle", "name": "Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting.", "datePublished": "2024-09-06", "url": "https://questionsmedicales.fr/article/39240335", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1084/jem.20240289" } }, { "@type": "ScholarlyArticle", "name": "Dynamics of SARS-CoV-2-Specific B Cell Memory Responses in Infected and Vaccinated Individuals.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37140898", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1089/vim.2022.0197" } }, { "@type": "ScholarlyArticle", "name": "Long-Term Effectiveness of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine on B Cell Compartment: Efficient Recall of SARS-CoV-2-Specific Memory B Cells.", "datePublished": "2022-11-30", "url": "https://questionsmedicales.fr/article/36499373", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms232315046" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétéromonocycliques", "item": "https://questionsmedicales.fr/mesh/D006573" }, { "@type": "ListItem", "position": 4, "name": "Pyrimidines", "item": "https://questionsmedicales.fr/mesh/D011743" }, { "@type": "ListItem", "position": 5, "name": "Dasatinib", "item": "https://questionsmedicales.fr/mesh/D000069439" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Dasatinib - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Dasatinib", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Dasatinib", "description": "Comment le Dasatinib est-il utilisé dans le diagnostic ?\nQuels tests sont nécessaires avant de commencer le Dasatinib ?\nLe Dasatinib est-il efficace pour tous les types de leucémie ?\nComment confirmer une réponse au traitement par Dasatinib ?\nLe Dasatinib nécessite-t-il un suivi régulier ?", "url": "https://questionsmedicales.fr/mesh/D000069439?mesh_terms=Memory+B+Cells&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Dasatinib", "description": "Quels sont les effets secondaires courants du Dasatinib ?\nLe Dasatinib peut-il provoquer des symptômes respiratoires ?\nQuels symptômes indiquent une réaction allergique au Dasatinib ?\nLe Dasatinib peut-il affecter le système digestif ?\nQuels signes de toxicité doivent alerter lors du traitement ?", "url": "https://questionsmedicales.fr/mesh/D000069439?mesh_terms=Memory+B+Cells&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Dasatinib", "description": "Peut-on prévenir les effets secondaires du Dasatinib ?\nY a-t-il des précautions à prendre avant de commencer le Dasatinib ?\nLe mode de vie influence-t-il l'efficacité du Dasatinib ?\nDes vaccinations sont-elles recommandées pendant le traitement ?\nComment gérer les interactions médicamenteuses avec le Dasatinib ?", "url": "https://questionsmedicales.fr/mesh/D000069439?mesh_terms=Memory+B+Cells&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Dasatinib", "description": "Comment le Dasatinib est-il administré ?\nQuelle est la posologie standard du Dasatinib ?\nLe Dasatinib peut-il être combiné avec d'autres traitements ?\nQuels sont les objectifs du traitement par Dasatinib ?\nLe traitement par Dasatinib nécessite-t-il des ajustements ?", "url": "https://questionsmedicales.fr/mesh/D000069439?mesh_terms=Memory+B+Cells&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Dasatinib", "description": "Quelles sont les complications possibles du traitement par Dasatinib ?\nLe Dasatinib peut-il causer des problèmes cardiaques ?\nComment surveiller les complications liées au Dasatinib ?\nLe Dasatinib peut-il affecter la fonction hépatique ?\nQuels signes doivent alerter sur une complication grave ?", "url": "https://questionsmedicales.fr/mesh/D000069439?mesh_terms=Memory+B+Cells&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Dasatinib", "description": "Qui est à risque de complications avec le Dasatinib ?\nL'âge influence-t-il la tolérance au Dasatinib ?\nLes femmes enceintes peuvent-elles prendre du Dasatinib ?\nY a-t-il des interactions alimentaires avec le Dasatinib ?\nLes antécédents de leucémie augmentent-ils le risque de complications ?", "url": "https://questionsmedicales.fr/mesh/D000069439?mesh_terms=Memory+B+Cells&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le Dasatinib est-il utilisé dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il n'est pas utilisé pour le diagnostic, mais pour traiter des leucémies diagnostiquées." } }, { "@type": "Question", "name": "Quels tests sont nécessaires avant de commencer le Dasatinib ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins pour évaluer la fonction hépatique et la numération des cellules sanguines." } }, { "@type": "Question", "name": "Le Dasatinib est-il efficace pour tous les types de leucémie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, il est principalement efficace pour la leucémie myéloïde chronique et la LAL." } }, { "@type": "Question", "name": "Comment confirmer une réponse au traitement par Dasatinib ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Par des tests sanguins réguliers pour surveiller les niveaux de cellules sanguines." } }, { "@type": "Question", "name": "Le Dasatinib nécessite-t-il un suivi régulier ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les effets." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants du Dasatinib ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, nausées, douleurs musculaires et éruptions cutanées sont fréquents." } }, { "@type": "Question", "name": "Le Dasatinib peut-il provoquer des symptômes respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut causer des problèmes respiratoires comme la toux ou la dyspnée." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réaction allergique au Dasatinib ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Éruptions cutanées, démangeaisons, gonflement du visage ou des lèvres." } }, { "@type": "Question", "name": "Le Dasatinib peut-il affecter le système digestif ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des nausées, vomissements et diarrhées peuvent survenir." } }, { "@type": "Question", "name": "Quels signes de toxicité doivent alerter lors du traitement ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Saignements inhabituels, fièvre persistante ou signes d'infection." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires du Dasatinib ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures comme une bonne hydratation et une alimentation équilibrée peuvent aider." } }, { "@type": "Question", "name": "Y a-t-il des précautions à prendre avant de commencer le Dasatinib ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer le médecin de toutes les allergies et médicaments en cours est crucial." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il l'efficacité du Dasatinib ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut améliorer la tolérance et l'efficacité du traitement." } }, { "@type": "Question", "name": "Des vaccinations sont-elles recommandées pendant le traitement ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations peuvent être nécessaires pour prévenir les infections." } }, { "@type": "Question", "name": "Comment gérer les interactions médicamenteuses avec le Dasatinib ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Consulter un médecin avant d'ajouter tout nouveau médicament pour éviter les interactions." } }, { "@type": "Question", "name": "Comment le Dasatinib est-il administré ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement pris par voie orale sous forme de comprimés." } }, { "@type": "Question", "name": "Quelle est la posologie standard du Dasatinib ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie varie, mais elle est souvent de 100 mg par jour pour la LMC." } }, { "@type": "Question", "name": "Le Dasatinib peut-il être combiné avec d'autres traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être utilisé en association avec d'autres thérapies ciblées." } }, { "@type": "Question", "name": "Quels sont les objectifs du traitement par Dasatinib ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Contrôler la maladie, réduire les symptômes et améliorer la qualité de vie." } }, { "@type": "Question", "name": "Le traitement par Dasatinib nécessite-t-il des ajustements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des ajustements peuvent être nécessaires en fonction des effets secondaires." } }, { "@type": "Question", "name": "Quelles sont les complications possibles du traitement par Dasatinib ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections, des saignements et des problèmes cardiaques." } }, { "@type": "Question", "name": "Le Dasatinib peut-il causer des problèmes cardiaques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut augmenter le risque de complications cardiaques chez certains patients." } }, { "@type": "Question", "name": "Comment surveiller les complications liées au Dasatinib ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des examens réguliers et des tests sanguins sont nécessaires pour détecter les complications." } }, { "@type": "Question", "name": "Le Dasatinib peut-il affecter la fonction hépatique ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut entraîner des anomalies des tests hépatiques chez certains patients." } }, { "@type": "Question", "name": "Quels signes doivent alerter sur une complication grave ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Saignements excessifs, douleurs thoraciques ou signes d'infection sévère." } }, { "@type": "Question", "name": "Qui est à risque de complications avec le Dasatinib ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents cardiaques ou des problèmes hépatiques sont à risque." } }, { "@type": "Question", "name": "L'âge influence-t-il la tolérance au Dasatinib ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir une tolérance réduite et des effets secondaires accrus." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles prendre du Dasatinib ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Non, le Dasatinib est contre-indiqué pendant la grossesse en raison de risques pour le fœtus." } }, { "@type": "Question", "name": "Y a-t-il des interactions alimentaires avec le Dasatinib ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains aliments peuvent affecter l'absorption du Dasatinib, comme le pamplemousse." } }, { "@type": "Question", "name": "Les antécédents de leucémie augmentent-ils le risque de complications ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients ayant des antécédents de leucémie peuvent avoir un risque accru." } } ] } ] }

Sources (10000 au total)

JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission.

To investigate the distribution and activation of B-cell subpopulations in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) and to analyze their correlation with disease... Peripheral blood samples were collected from 23 adult healthy controls and 58 RA patients, 31 of whom were treated with JAKis and assessed during a 24-month follow-up. The number of peripheral B-cell ... Compared with that in healthy controls, the frequency of NSMB cells was significantly lower in new-onset untreated RA patients. However, expression of CD40, CD80, CD95, CD21... RA patients present different B-cell subpopulations, in which the frequency of NSMB cells is negatively associated with disease activity. However, treatment with JAKis can inhibit activation of NSMB c...

Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis.

Regulatory B cells (Bregs) play a pivotal role in suppressing immune responses, yet there is still a lack of cell surface markers that can rigorously identify them. In mouse models for multiple sclero... FACS-sorted TIM-1+/-TIGIT+/- memory B (memB) cells co-cultured with allogenic CD4+ T cells were analyzed for proliferation and induction of inflammatory markers using flow cytometry and cytokine quant... TIM-1-TIGIT- double negative (DN) memB cells strongly induce T cell proliferation and pro-inflammatory cytokine expression. The TIM-1+ memB cells enabled low levels of CD4+ T cell activation and gave ... These findings demonstrate that TIM-1/TIGIT expressing memory B cell subsets have distinct functionalities. Co-expression of TIM-1 and TIGIT defines a regulatory memory B cell subset that is functiona...

Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection.

Follicular helper T cells are essential for helping in the maturation of B cells and the production of neutralizing antibodies (NAbs) during primary viral infections. However, their role during recall... We evaluated this interaction longitudinally in subjects who have spontaneously resolved primary HCV infection during a subsequent reinfection episode that resulted in either another spontaneous resol... Both groups exhibited virus-specific memory T cells that expanded upon reinfection. However, early expansion of activated cTfh (CD4... These results underscore a key role for early activation of cTfh1 cells in helping antigen-specific B cells to produce NAbs that mediate the clearance of HCV reinfection....

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.

Immunogenicity of acellular pertussis (aP) vaccines is conventionally assessed by measuring antibody responses but antibody concentrations wane quickly after vaccination. Memory B cells, however, are ... We studied pertussis specific memory B cell (re)activation induced by an aP booster vaccination in four different age groups within three countries.... From a phase IV longitudinal interventional study, 268 participants across Finland, the Netherlands and the United Kingdom were included and received a 3-component pertussis booster vaccine: children ... Geometric mean (GM) memory B cell frequencies for pertussis antigens at baseline were low. At 28 days post-vaccination, these frequencies increased within each age group and were still elevated one ye... An aP booster vaccine (re)activated memory B cells in all age groups. Still elevated memory B cell frequencies after one year indicates enhanced immunological memory. However, antigen specific memory ...